Emerging data suggest this peptide, a dual stimulator targeting both incretin and GIP , could represent a notable development for obesity management . Preliminary patient investigations have shown considerable losses in body mass , possibly surpassing other body composition medications . Nevertheless , more study is necessary to fully assess its lo